Cargando…
CART Cell Toxicities: New Insight into Mechanisms and Management
T cells genetically engineered with chimeric antigen receptors (CART) have become a potent class of cancer immunotherapeutics. Numerous clinical trials of CART cells have revealed remarkable remission rates in patients with relapsed or refractory hematologic malignancies. Despite recent clinical suc...
Autores principales: | Zahid, Anas, Siegler, Elizabeth L., Kenderian, Saad S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Atlantis Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785104/ https://www.ncbi.nlm.nih.gov/pubmed/33409484 http://dx.doi.org/10.2991/chi.k.201108.001 |
Ejemplares similares
-
In vivo CART cell imaging: Paving the way for success in CART cell therapy
por: Sakemura, Reona, et al.
Publicado: (2021) -
Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies
por: Siegler, Elizabeth L., et al.
Publicado: (2020) -
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity
por: Cox, Michelle J., et al.
Publicado: (2022) -
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
por: Kankeu Fonkoua, Lionel A., et al.
Publicado: (2022) -
P1359: TUMOR-SPECIFIC, T-CELL-TARGETING MICRORNA IS ASSOCIATED WITH CART CELL FAILURE IN B CELL MALIGNANCIES
por: Chohan, Karan, et al.
Publicado: (2023)